BOSTON, Mass. - July 27, 2016 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, ...
Today during the Society of NeuroInterventional Surgery's (SNIS) 13th Annual Meeting, SNIS President Donald Frei, MD, announced that the Penumbra 3D Trial successfully met the primary trial endpoints, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果